Identification of pregnant women with DFR genotype and discussion of prenatal examination strategy
10.13303/j.cjbt.issn.1004-549x.2022.03.025
- VernacularTitle:DFR变异型孕妇血型鉴定及孕期监测策略探讨
- Author:
Jizhi WEN
1
,
2
;
Shuangshuang JIA
1
,
2
;
Jingwang CHEN
1
,
2
;
Ling WEI
1
,
2
;
Guangping LUO
1
,
2
;
Yanli JI
1
,
2
Author Information
1. Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou 510095, China
2. The Key Medical Laboratory of Guangzhou
- Publication Type:Journal Article
- Keywords:
DFR;
hybrid RHD-CE-D allele;
D variants;
Rh blood group system.
- From:
Chinese Journal of Blood Transfusion
2022;35(3):327-330
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To identify three cases of pregnant women with the D variant phenotype using serological and molecular tests, and discuss the strategy of prenatal examination. 【Methods】 The peripheral blood samples from three pregnant women with the D variant phenotype were collected. RhD variant phenotype was determined using routine serological methods with two different kinds of monoclonal anti-D. The serological characteristic for the epitope of D antigen was further analyzed using the commercial panel anti-D reagents (D-Screen, Diagast). The hybrid RHD-CE-D allele was analyzed by the Multiplex Ligation-dependent Probe Amplification (MLPA) assay and polymerase chain reaction with sequence specific primers (PCR-SSP) method. Further Sanger sequencing of RHD gene exons was also performed. 【Results】 DFR phenotype was primarily determined by serological characteristic for the epitope of D antigen. RHD*DFR2/01N.01(n=2) and RHD*DFR1/1227A(n=1) genotypes were identified by the MLPA assay, PCR-SSP and Sanger sequencing. 【Conclusion】 Two pregnant women with RHD*DFR2/01N.01 genotype should be treated as D negative patients clinically, while the pregnant woman with RHD*DFR1/1227A genotype can be treated as Asia type DEL to avoid unnecessary antibody screening and anti-D prophylaxis.
